Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 431,861Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/08/13/2929628/0/en/Tenax-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html

GLOBENEWSWIRE
13 Aug 2024

https://www.globenewswire.com/news-release/2024/04/30/2872119/0/en/Tenax-Therapeutics-Announces-New-U-S-Patent-Covering-the-Use-of-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html

GLOBENEWSWIRE
30 Apr 2024
Tenax Therapeutics Hosts KOL Event
Tenax Therapeutics Hosts KOL Event

09 Apr 2024

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2024/04/09/2859987/0/en/Tenax-Therapeutics-to-Host-KOL-Event-LEVEL-Setting-the-Scientific-Rationale-for-Levosimendan-as-a-Potential-First-Treatment-for-PH-HFpEF-and-the-Ongoing-Phase-3-LEVEL-Study.html

GLOBENEWSWIRE
09 Apr 2024

https://www.globenewswire.com/news-release/2024/03/28/2854007/0/en/Tenax-Therapeutics-Provides-Business-and-Clinical-Development-Updates-with-Full-Year-2023-Financial-Results.html

GLOBENEWSWIRE
28 Mar 2024

https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275

PRESS RELEASE
29 Feb 2024

https://www.globenewswire.com//news-release/2024/02/20/2831850/0/en/Tenax-Therapeutics-Announces-Global-License-Amendment-that-Significantly-Expands-Rights-to-Levosimendan.html

GLOBENEWSWIRE
20 Feb 2024